Overview

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Status:
Not yet recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. The study is blinded and placebo controlled with half of the patients receiving BXQ-350 and half receiving placebo (normal saline).

Phase:

Early Phase 1

Details

Lead Sponsor:

Bexion Pharmaceuticals, Inc.

Collaborator:

CTI Clinical Trial and Consulting Services